Mineral-Homeostasis in Continuous Renal Replacement Therapy

Acute Renal Failure Clinical Trial

Official title:

Phosphate, Magnesium and Calcium-Homeostasis in Patients With Acute Renal Failure and Continuous Renal Replacement Therapy

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01946113
• Other study ID #: 4209
• Status: Completed
• Phase: N/A
• First received: September 9, 2013
• Last updated: August 19, 2015
• Start date: September 2013
• Est. completion date: August 2015

Study information

• Verified date: August 2015
• Source: Heinrich-Heine University, Duesseldorf
• Contact: n/a
• Is FDA regulated: No
• Health authority: Germany: Ethics Commission
• Study type: Observational

Clinical Trial Summary

Acute renal failure is a common complication in intensive care unit patients. In 10% of cases renal replacement therapy becomes necessary. Current devices have increase filter patency and efficacy. However, magnesium, calcium and phosphate are eliminated as well. However, the extend of this elimination hase not been quantified. Thus, we want to

1. record retrospectively how often abnormal values for phosphate, magnesium and calcium occurred during routine renal replacement therapy in 2011 and 2012.

2. prospectively evaluate the same parameters during routine treatment in 2013 and 2014

Recruitment information / eligibility

• Status: Completed
• Enrollment: 200
• Est. completion date: August 2015
• Est. primary completion date: August 2015
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• intensive care unit patients with acute renal failure undergoing continuous renal replacement therapy

• older than 18 years of age

Exclusion Criteria:

• age less than 18 years

• pregnancy

• contraindications against continuous renal replacement therapy

Study Design

Observational Model: Cohort

Related Conditions & MeSH terms

• Acute Kidney Injury
• Acute Renal Failure
• Renal Insufficiency

Locations

Country	Name	City	State
Germany	Interdisziplinäre Intensivstation Universitätsklinikum Düsseldorf	Düsseldorf

Sponsors (1)

Lead Sponsor	Collaborator
Heinrich-Heine University, Duesseldorf

Country where clinical trial is conducted

Germany, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidence of hypo-phosphate,-magnesium and calcaemia	Participants will be followed for the duration of ICU stay, an expected average of 28 days	approximately 28 days	No